普瑞巴林对儿童青少年后路脊柱融合术后持续性疼痛的影响:一项随机临床试验
结果显示普瑞巴林未减少术后48小时累积阿片消耗量,也未降低持续性术后疼痛发生率。
要点
- 普瑞巴林2 mg/kg每日两次围手术期给药未减少术后48小时累积阿片消耗量。
- 普瑞巴林未降低2年随访期间持续性术后疼痛发生率。
- 两组SRS-24疼痛域评分及总分在各时间点均无显著差异。
核心结论
- 围手术期普瑞巴林不能减少青少年脊柱畸形后路内固定融合术后阿片消耗量或持续性术后疼痛发生率。
主要发现
- 两组术后48小时累积阿片消耗量无显著差异。
- SRS-24疼痛域评分从两组均值3.8分别改善至2年时普瑞巴林组4.3和安慰剂组4.0,各时间点组间无差异(p=0.317)。
- 两组SRS-24总分相似(p=0.678)。
- 视觉模拟量表背痛评分显著改善(p=0.001),但术前及术后6个月、1年、2年各时间点组间无显著差异。
关键数值与推荐
- 普瑞巴林剂量为2 mg/kg,术前及术后5天每日两次。
- 主要结局为术后48小时累积阿片消耗量和2年随访期间持续性术后疼痛发生率。
- 证据等级为治疗性I级。
临床怎么用
- 对于青少年脊柱畸形后路融合术,不应期望围手术期普瑞巴林能减少阿片用量或预防持续性术后疼痛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical correction of spinal deformity requires major surgical intervention with extensive manipulation of the spine and neural elements. Persistent postoperative pain affects patient quality of life and can also cause financial burden for patient families and for society. We aimed to investigate the effect of perioperative pregabalin on the incidence of persistent pain following instrumented spinal fusion. METHODS: We conducted a randomized, double-blinded, and placebo-controlled single-center clinical trial. Adolescents and children 10 to 21 years old with a spinal deformity who were scheduled for pedicle screw instrumentation and fusion were randomized into either the pregabalin or placebo group. Patients received 2 mg/kg of pregabalin or a placebo twice daily preoperatively and for 5 days postoperatively. The duration of follow-up was 2 years. The primary outcomes were cumulative opioid consumption during the first 48 hours postoperatively and the incidence of persistent postoperative pain over the course of the 2-year follow-up. RESULTS: Sixty-four of 77 eligible patients were enrolled in the study, with all patients completing the 2-year follow-up. Thirty-three patients were randomized into the pregabalin group and 31 into the placebo group. There was no significant difference in cumulative 48-hour opioid consumption between the study groups. The Scoliosis Research Society 24-Item Questionnaire pain domain score improved significantly, from a mean value of 3.8 in both groups to 4.3 in the pregabalin and 4.0 in the placebo group at 2 years postoperatively, with no differences between the study groups at any time point (p = 0.317). The Scoliosis Research Society total scores of the study groups were similar (p = 0.678). Back pain, as measured with use of a visual analogue scale, improved significantly (p = 0.001) with no significant differences at any time point (preoperatively and 6 months, 1 year, and 2 years postoperatively). CONCLUSIONS: Perioperative pregabalin does not reduce postoperative opioid consumption or the incidence of persistent postoperative pain following instrumented posterior spinal fusion for spinal deformities in an adolescent population. LEVEL OF EVIDENCE: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.
引用
- Helenius L, Yrjälä T, Oksanen H, et al. Pregabalin and Persistent Postoperative Pain Following Posterior Spinal Fusion in Children and Adolescents: A Randomized Clinical Trial. J Bone Joint Surg Am. 2021. PMID: 34424869. doi:10.2106/JBJS.21.00153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。